BMF

Across TCGA pan-cancer cohorts, BMF RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated BMF data layer compared with 2 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher BMF RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated BMF expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCS show a favorable association.

LIHC, HNSC, and UCS are the cancer types where BMF RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.440	0.604	.002	88	view →
HNSC	DFS	Tertile	All	0.802	0.652	<.001	71	view →
UCS	DFS	Quartile	II,III,IV	0.599	0.139	.008	50	view →
KIRP	DFS	Tertile	IV	0.045	0.765	.006	40	view →
LGG	OS	Tertile	All	0.372	0.658	<.001	35	view →
LUAD	OS	Tertile	All	0.827	0.680	.003	25	view →
PAAD	DFS	Quartile	II,III,IV	0.539	0.216	.002	18	view →
LAML	DFS	Tertile	All	0.282	0.507	.021	12	view →
THYM	OS	Tertile	All	1.000	0.707	.004	9	view →
SKCM	DFS	Median	IV	0.677	0.139	.005	9	view →
LUSC	OS	Tertile	III,IV	0.212	0.786	.019	8	view →
CESC	OS	Tertile	IV	0.684	0.336	.033	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

BMF–LIHC (DFS)

Open the LIHC breakdown →